Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsSector newsTweets

Johnson & Johnson : 35 years later, Tylenol deaths still unsolved

share with twitter share with LinkedIn share with facebook
share via e-mail
10/05/2017 | 12:55pm CET

In 1982, cyanide-laced Tylenol capsules killed seven people in the Chicago area, sparking one of the first massive recalls in the United States and revolutionizing packaging for over-the-counter medications sold in the country. But the case has never been solved.

The deaths began on Sept. 29, when 12-year-old Mary Kellerman died within hours of taken a capsule of Extra-Strength Tylenol. Later that same day, a postal worker, Adam Janus died. Both had been poisoned with potassium cyanide, which investigators later determined had been put inside the capsules of Tylenol.

Another five people would die, including Adam Janus' brother, Stanley Janus and sister-in-law Theresa Janus, who had taken capsules from the same bottle of Tylenol that killed the postal worker. Mary McFarland, Paula Prince and Mary Reiner, all living in or near Chicago, also died. Tylenol samples taken from each of the victims' homes tested positive for cyanide.

The results of the test prompted one of the first massive recalls in U.S. history. Thirty-five years ago today, on Oct. 5, 1982, Johnson & Johnson, the maker of Tylenol, pulled millions of dollars worth of product off store shelves, reducing the company's earnings by $50 million. There was nationwide panic as worried consumers went to hospitals out of fear of poisoning. The Food and Drug Administration counted hundreds of copycat incidents nationwide, including one in 1986 in which two people in died after taking cyanide-laced Excedrin capsules.

Investigators believe someone pulled packages of the capsules off the shelf, opened up the capsules and replaced the drug inside with cyanide before putting the packages back on the shelf. The ease with which capsules can be contaminated prompted drugmakers to move away from capsules and instead produce solid caplets. Companies also began implementing the use of tamper-resistant packaging for the drugs.

Despite the far-reaching impact of the case, the FBI never solved the question of who was responsible for the tampering.

The only person convicted in relation to the case was James Lewis, who sent a letter to Johnson & Johnson demanding $1 million in order to "stop the killings." He spent 12 years in prison for extortion, but police never charged him with tampering with the capsules.

In 2011, the FBI investigated the possibility so-called "Unabomber" Theodore Kaczynski, who grew up in the Chicago area, may have been behind the killings.

The Chicago Daily Herald said the FBI handed over the case to the Arlington Heights, Ill., Police Department. Deputy Chief Mike Hernandez told the newspaper the department is concerned too much time has passed in order to solve the crime.

"We're concerned about how long it's been. It's been a concern of the task force, as more time goes by," he said.

Years after the initial deaths, advances in technology allowed investigators to potential DNA evidence and a fingerprint smudge on one of the Tylenol bottles. But neither resulted in any arrests.

Though investigators on the case no longer regularly meet, the Daily Herald said, Hernandez said there's still hope.

"But this case is still a high priority. It's not gathering dust," he said.

Copyright 2017 United Press International, Inc. (UPI). Any reproduction, republication, redistribution and/or modification of any UPI content is expressly prohibited without UPI's prior written consent., source US Top News

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on JOHNSON & JOHNSON
03/23CIPLA : gets tentative approval for gPrezista
03/23JOHNSON & JOHNSON : Biopharmaceutical Industry Marks World TB Day
03/23GSK's two-drug HIV regimen wins European panel approval
03/23OMNICOM : Inside J&J's Effort to Cut Costs and Drive Integration at Ad Firms WPP..
03/23Glaxo in pole position in race for £14bn rival
03/22+10% CAGR GROWTH TO BE ACHIEVED BY D : Know about Digital Marketing Spending Mar..
03/22JOHNSON & JOHNSON : Janssen Announces U.S. FDA Breakthrough Therapy Designation ..
03/22JOHNSON & JOHNSON : Announces Binding Offer from Platinum Equity to Acquire Life..
03/22JOHNSON & JOHNSON : Dominic J. Caruso to Retire as Chief Financial Officer of Jo..
03/22JOHNSON & JOHNSON : to Host Investor Conference Call on First-Quarter Results
More news
News from SeekingAlpha
03/23Alzheon Files To Raise $80 Million In U.S. IPO 
03/23European advisory group backs Novartis biosimilar to J&J's Remicade 
03/23How To Retire At 64 With Only Half A Million 
03/22AstraZeneca Looks To Prove Itself In The Type 2 Diabetes Market 
03/22Rituxan biosimilar captures 80% of British market 
Financials ($)
Sales 2018 81 115 M
EBIT 2018 24 940 M
Net income 2018 19 683 M
Debt 2018 12 439 M
Yield 2018 2,88%
P/E ratio 2018 17,37
P/E ratio 2019 16,30
EV / Sales 2018 4,29x
EV / Sales 2019 3,95x
Capitalization 336 B
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | 4-Traders
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 150 $
Spread / Average Target 20%
EPS Revisions
Alex Gorsky Chairman & Chief Executive Officer
Dominic J. Caruso Chief Financial Officer & Vice President
Paulus Stoffels Chief Scientific Officer & Executive VP
Charles O. Prince Independent Director
William David Perez Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON-8.83%335 598
NOVARTIS-7.31%207 583
PFIZER-1.71%205 314
ROCHE HOLDING LTD.-12.37%196 669
MERCK AND COMPANY-5.08%144 004
AMGEN-2.57%122 085